Parametric CC Developed Intl Local-TM (S:0P0001DH4S)
18.23
-1.07
(-5.57%)
USD |
Oct 31 2024
Returns Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Key Stats
| Maximum Management Fee | Annualized Total Returns Since Inception (Daily) | Alpha (vs Category) (3Y) | Forecasted Dividend Yield |
|---|---|---|---|
| -- | -- | -- | -- |
| Total Market Value (Net) | Beta (vs Category) (3Y) | Max Drawdown (Since Inception) | Fwd Dividend Yield (Long) |
| Upgrade | Upgrade | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| General | |
| Security Type | |
| Equity Style | |
| Fixed Income Style | |
| Broad Asset Class | |
| Broad Category | |
| Category Name | |
| Category Index | |
| Global Category Name | |
| YCharts Categorization | Global Equity |
| YCharts Benchmark | MSCI World Total Return (^MSWTR) |
| Fund Owner Firm Name | |
| Prospectus Benchmark Index | |
| MSCI EAFE NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| 100.0% | |
| Manager Tenure | |
| Paul Bouchey | 8.09 yrs |
| Thomas Seto | 8.09 yrs |
| Jennifer Sireklove | 5.34 yrs |
| Thomas Lee | 5.01 yrs |
| Jeremy Milleson | 3.34 yrs |
Annual Total Returns Versus Peers
As of November 15, 2024.
Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | -- | -- | -- |
| Stock | -- | -- | -- |
| Bond | -- | -- | -- |
| Convertible | -- | -- | -- |
| Preferred | -- | -- | -- |
| Other | -- | -- | -- |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Novo Nordisk AS Class B | 2.48% | 105.79 | 0.93% |
| ASML Holding NV | 2.22% | 692.80 | 5.40% |
| SAP SE | 1.66% | 234.08 | 2.14% |
| Nestle SA | 1.65% | 88.26 | 0.84% |
| Atlas Copco AB Class B | 1.35% | 15.76 | 0.00% |
| Lvmh Moet Hennessy Louis Vuitton SE | 1.30% | 614.57 | 1.82% |
| Roche Holding AG | 1.29% | 289.09 | -1.96% |
| Novartis AG Registered Shares | 1.28% | 104.00 | -0.91% |
| AstraZeneca PLC | 1.20% | 130.24 | 0.81% |
| Schneider Electric SE | 1.11% | 258.64 | 1.70% |
Fees & Availability
| Fees | |
| Negotiable Fee | No |
| Administrative Fee | -- |
| Maximum Management Fee | -- |
| Prospectus Custodian Fee | -- |
| Trustee Fee | -- |
| Purchase Details | |
| Open to New Investors | No |
| Open to Existing Investors | No |
| Minimum Initial Investment | -- |
| Minimum Subsequent Investment | -- |
Basic Info
| Investment Strategy | |
| General | |
| Security Type | |
| Equity Style | |
| Fixed Income Style | |
| Broad Asset Class | |
| Broad Category | |
| Category Name | |
| Category Index | |
| Global Category Name | |
| YCharts Categorization | Global Equity |
| YCharts Benchmark | MSCI World Total Return (^MSWTR) |
| Fund Owner Firm Name | |
| Prospectus Benchmark Index | |
| MSCI EAFE NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| 100.0% | |
| Manager Tenure | |
| Paul Bouchey | 8.09 yrs |
| Thomas Seto | 8.09 yrs |
| Jennifer Sireklove | 5.34 yrs |
| Thomas Lee | 5.01 yrs |
| Jeremy Milleson | 3.34 yrs |
Fundamentals
| Number of Holdings | -- |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | -- |
| Weighted Average Price to Book Ratio | -- |
| Weighted Median ROE | -- |
| Weighted Median ROA | -- |
| Forecasted Dividend Yield | -- |
| Forecasted PE Ratio | -- |
| Forecasted Price to Sales Ratio | -- |
| Forecasted Price to Book Ratio | -- |
Fund Details
| Key Dates | |
| Inception Date | -- |
| Last Annual Report Date | -- |
| Last Prospectus Date | -- |
| Attributes | |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |